Question to the Department of Health and Social Care:

To ask His Majesty's Government what reasons the RAPID C-19 initiative gave for advising them against providing Evusheld to the immunocompromised in the UK.

The decision not to procure Evusheld for prevention through emergency routes at this time is based on independent clinical advice by the multi-agency RAPID C-19 and a United Kingdom national expert policy working group. These groups considered a range of evidence, including clinical trial data, in vitro analysis and emerging observational studies. Following a review of this evidence, RAPID C-19 concluded that the quality of data is insufficient to warrant action to progress to patient access.

The Chief Medical Officer for England is content that the correct process for providing clinical advice has been followed and this should now be referred to the National Institute for Health and Care Excellence for further evaluation.